(Q36516553)

14 August 2017

1 reference

title

T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature (English)

1 reference

T-cell large granular lymphocyte leukemia

14 August 2017

main subject

0 references

8

Daniel Catovsky

1 reference

14 August 2017

2

Estella Matutes

1 reference

14 August 2017

6

Andrew Wotherspoon

1 reference

14 August 2017

Geir Erland Tjønnfjord

series ordinal

3

object named as

Geir Tjonnfjord

1 reference

14 August 2017

7

John G Swansbury

1 reference

14 August 2017

1

Nnenna Osuji

1 reference

14 August 2017

5

Ilaria Del Giudice

1 reference

14 August 2017

4

Henri Grech

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

107

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

570-578

1 reference

Chronic lymphocytic leukaemia of T-cell origin. Immunological and clinical evaluation in eleven patients

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Chronic lymphoproliterative disorder with unusual clinical, morphologic, ultrastructural and membrane surface marker characteristics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Current concepts: large granular lymphocyte leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Clinical features of large granular lymphocyte leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Improvement of extrathymic T cell type of large granular lymphocyte (LGL) leukemia by cyclosporin A: the serum level of Fas ligand is a marker of LGL leukemia activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Resolution of autoimmune hemolytic anemia following splenectomy in CD3+ large granular lymphocyte leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Large granular lymphocyte (LGL)-like clonal expansions in paroxysmal nocturnal hemoglobinuria (PNH) patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Association of clonal T-cell large granular lymphocyte disease and paroxysmal nocturnal haemoglobinuria (PNH): further evidence for a pathogenetic link between T cells, aplastic anaemia and PNH

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Epitope mapping of HTLV envelope seroreactivity in LGL leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Cyclosporine A alleviates severe anaemia associated with refractory large granular lymphocytic leukaemia and chronic natural killer cell lymphocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Neutropenia and anaemia associated with T-cell large granular lymphocyte leukaemia responds to fludarabine with minimal toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Induction of clinical remission in T-large granular lymphocyte leukemia with cyclosporin A, monitored by use of immunophenotyping with Vbeta antibodies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Severe neutropenia associated with large granular lymphocyte lymphocytosis: successful control with cyclosporin A

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Severe neutropenia in T-large granular lymphocyte leukemia corrected by intensive immunosuppression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Multidrug resistance analysis in lymphoproliferative disease of large granular lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Evidence that natural killer cells express mini P-glycoproteins but not classic 170 kDa P-glycoprotein.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Lessons from a case of T-cell large granular lymphocytic leukaemia suggesting that immunomodulatory therapy is more effective than intensive treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

HLA‐DR4 predicts haematological response to cyclosporine in T‐large granular lymphocyte lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Low-dose methotrexate for the treatment of patients with large granular lymphocyte leukemia associated with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

2-deoxycoformycin in the treatment of T-large granular lymphocyte leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Cd8(+)/V beta 5.1(+) large granular lymphocyte leukemia associated with autoimmune cytopenias, rheumatoid arthritis and vascular mammary skin lesions: successful response to 2-deoxycoformycin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Transformation of T-cell large granular lymphocyte leukaemia into a high-grade large T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti‐CD52 monoclonal antibody alemtuzumab (Campath‐1H)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22032

7 January 2021

Identifiers

DOI

10.1002/CNCR.22032

1 reference

14 August 2017

1 reference